Islamic Finance Principles Assessment
Riba — Does Enzyme involve interest?
Enzyme's protocol-level revenue itself is fee-based (an AUM access fee), not interest income, which is a positive. However, the protocol's own vault architecture directly enables interest-bearing lending and borrowing through native features and named integrations. For Muslim investors, this built-in exposure to conventional lending markets is the central riba concern and warrants real caution.
Assessment: Riba Dominant
Score: 46.6/100
Our methodology examines 10 criteria to evaluate how well Enzyme avoids interest-based mechanisms.
Enzyme's protocol revenue comes from a 50 basis-point annualized fee on assets under management, discounted to 25bps if paid in MLN, with collected fees minted and later bought back and burned. This fee model is service-based rather than interest-based, which is a favorable structural point. However, sources note inflation is expected to exceed burn "for many years," and treasury composition beyond the fee-reserve contract is not detailed, leaving open the question of whether idle treasury assets are held in interest-bearing instruments.
More significant is Enzyme's core business function: vaults built on the protocol's "Sulu" release include a native Borrow tab with Collateral Factor and Borrow Rate/APY fields, and documented integrations with Aave V2/V3 and Alpha Homora — interest-bearing lending markets. A company blog explicitly frames this in repo and securities-lending terms. Because this borrowing/lending capability is built into the first-party vault interface rather than being an optional third-party plug-in, any fund manager using it is directly engaging clients' pooled capital with conventional, interest-based credit markets.
Gharar — How much uncertainty does Enzyme involve?
Uncertainty around Enzyme is moderate: the founder and governance council are named and traceable, and multi-year documentation reduces informational opacity. What increases gharar is the absence of any comprehensive core-contract audit and unclear treasury/token-allocation disclosure. On balance, transparency of people is solid, but transparency of code assurance and token economics is thin.
Assessment: Moderate Gharar (Material Uncertainty)
Score: 52/100
Our methodology examines 15 criteria including team transparency, audit quality, and governance.
Enzyme was founded by Mona El Isa, a named, credentialed figure (former Goldman Sachs VP, Avantgarde Finance CEO), and governance now rests with the Enzyme Council, whose Technical Council and User Representative members are also named individuals (e.g., Janos Berghorn, Felix Hartmann, Fabian Gompf, Will Harborne). Public documentation, an SDK, and a specifications repository exist. This is a genuine, identifiable infrastructure project rather than an anonymous venture, though independent verification of team claims beyond public bios and LinkedIn remains limited.
Documentation is extensive — developer hub, SDK, specs and FAQ pages are publicly available — but audit coverage is thin. The only audit located is a 2021 Dedaub review of a GSN meta-transaction forwarder component, which found no issues; no comprehensive, named-firm audit of Enzyme's core vault or accounting contracts appears in the record. For a protocol managing pooled third-party assets, this absence of a full audit trail on the core logic is a legitimate gharar concern and should be treated as such by any investor evaluating fund-level risk.
Maysir — Does Enzyme involve gambling or speculation?
Enzyme's underlying protocol is a functioning asset-management infrastructure, not a gambling mechanism, which distinguishes it from pure speculation vehicles. The greater maysir-adjacent concern lies with the MLN token itself, whose value-accrual mechanics are openly uncertain. Overall, the protocol's utility is real, but the token's secondary-market dynamics carry speculative traits investors should weigh carefully.
Assessment: Moderate Maysir (High Risk)
Score: 54.7/100
Our methodology examines 11 criteria to determine whether Enzyme is a gambling instrument or a genuine economic tool.
MLN is documented as a utility token whose main function is a 50 percent discount on protocol access fees, with a burn mechanism tied to fee collection. Yet sources explicitly note that ongoing MLN inflation is expected to outpace burns "for many years," and state collected MLN is "unlikely to offer any value to the MLN token." Absent staking, direct governance voting, or a clear value-capture link between protocol growth and token price, MLN's market pricing leans heavily on speculative anticipation of future scarcity rather than a demonstrated, present economic claim.
Weighed against this, Enzyme's underlying protocol does perform a genuine economic function — enabling tokenized vaults, DAO treasury management, and RWA structuring with multi-year operating history and a real user base. This is meaningfully different from assets with no productive purpose. Still, because MLN's own tokenomics leave value accrual unresolved and governance sits with a council rather than token holders, secondary-market trading of MLN itself is likely to be driven more by price speculation than by a clear, verifiable link to protocol cash flows, a distinction Muslim investors should weigh independently of the protocol's genuine utility.
The Full 27-Point Screening
1. Legitimacy (4 criteria)
| Criterion | Score | Analysis |
|---|
| Team Transparency | 82/100 | Founder Mona El Isa and Enzyme Council members are named with verifiable professional histories. |
| Fraud & Scam Risk | 68/100 | No fraud, hack, or rug-pull reports appear in sources and the project has a multi-year track record, though this is inferred from absence of negative findings rather than a dedicated risk review. |
| Use Case Legitimacy | 78/100 | Sources describe clear real-world utility as on-chain asset-management/tokenization infrastructure with multiple documented use cases. |
| Ethical Practices | 35/100 | The protocol's own documented design embeds native interest-based borrowing (Sulu release "Borrow" feature and Aave/Alpha Homora integrations), which is a first-party design choice rather than incidental third-party misuse. |
Summary: Enzyme has a named, credentialed founder and governing council with a multi-year track record and no evident fraud or hack reports in these sources.
2. Project Operations (9 criteria)
| Criterion | Score | Analysis |
|---|
| Core Protocol Business | 40/100 | Core business is legitimate asset-management/tokenization infrastructure, but the protocol itself documents and enables interest-based lending/borrowing as a built-in feature. |
| Transaction Fees | 55/100 | Fees are a documented AUM-based access charge settled via mint-and-burn of MLN, but sources note the burn is likely to lag inflation for years, undermining a clean fee-burn model. |
| Treasury Assets | 50/100 (low evidence) | Sources describe only the fee-reserve contract mechanics; no detail on broader treasury asset composition or interest-bearing holdings could be found. |
| Revenue Model | 58/100 | Documented revenue comes from a usage-based AUM fee rather than being explicitly interest-derived at the protocol's own income level, though broader revenue streams (e.g., from newer product lines) are not detailed. |
| Transparency | 72/100 | Extensive public documentation, specs, SDK and developer hub pages are available, though explicit "open-source" licensing language was not found. |
| Governance | 45/100 | Governance is exercised by a defined Enzyme Council of named individuals rather than demonstrated broad decentralised token-holder voting. |
| Launch Fairness | 50/100 (low evidence) | No concrete data on initial token sale, pre-mine, or insider allocation could be found in these sources; a tokenomics table intended to show this was blank. |
| Token Distribution | 50/100 (low evidence) | Specific distribution percentages for MLN were not available in the retrieved sources. |
| Speculation/Utility Ratio | 68/100 | Documentation frames MLN explicitly as a utility/access token tied to protocol fees rather than a speculative or meme asset. |
Summary: The protocol provides genuine on-chain asset-management infrastructure but has, as a first-party feature, built-in interest-based borrowing and lending-market integrations alongside an AUM-based fee-burn mechanism and council-led governance.
3. Financial Health (4 criteria)
| Criterion | Score | Analysis |
|---|
| Protocol Revenue | 55/100 | Protocol revenue is fee-based on AUM rather than explicitly interest-based, but the full revenue mix is not detailed in sources. |
| Financial Status | 50/100 (low evidence) | No market cap, treasury size, or financial-stability data for Enzyme/MLN was found in the sources. |
| Interest Assessment | 20/100 | The base protocol itself provides a native borrowing feature with documented APY/interest terms and integrates with interest-bearing lending markets like Aave, placing interest-based mechanics at the protocol level, not merely in third-party apps. |
| Audit Quality | 25/100 | Only a narrow Dedaub audit of a peripheral meta-transaction forwarder (Oct 2021) was found; no comprehensive audit of Enzyme's core vault/accounting contracts by a named firm appears in these sources. |
Summary: Protocol revenue is fee-based, but the base protocol itself enables interest-bearing borrowing/lending, and only a narrow, non-comprehensive audit was found in the sources.
4. Token Economics (5 criteria)
| Criterion | Score | Analysis |
|---|
| Token Purpose | 68/100 | MLN is explicitly documented as a utility token for protocol access/fee discounts, not marketed as a meme asset. |
| Governance Rights | N/A | Sources show governance run by the Enzyme Council rather than direct MLN holder voting, but no explicit statement confirms MLN carries no governance rights at all. |
| Rewards Distribution | 55/100 | MLN's dynamics are usage-linked (fee-triggered burns) rather than a fixed/guaranteed payout, though inflation for development funding complicates a clean reward-from-activity narrative. |
| Speculation Controls | 32/100 (low evidence) | No vesting locks, sale caps, or other anti-speculation mechanisms for MLN were described in the sources. |
| Asset Backing | 40/100 | MLN is not asset-backed; its value rests on protocol utility and a fee-burn mechanism which sources themselves say is unlikely to offset inflation for years. |
Summary: MLN functions as a documented utility/access token with inflation-and-burn dynamics rather than clear governance rights, anti-speculation controls, or tangible backing.
5. Staking Mechanism
Enzyme has no native staking mechanism, so these five criteria are not applicable and are excluded from the score entirely rather than counted as zeros.
Overall Assessment: Enzyme presents as a legitimate, transparently-led infrastructure project, but its own protocol-level integration of interest-based lending/borrowing and its thin audit coverage are the most significant Shariah-relevant concerns identified from these sources.
Scoring note: Meme coin: maysir-capped (C13=68); score already below the cap.
Written by ThanvirFounder, Ex Director S&P Global Energy
Reviewed by Imam Omar SiddiqiShariah Scholar